Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA
PaperCitations, authors & open-access status
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 26 citations, 2023 year and closed oa status.
26
Citations
2023
Year
closed
OA Status